Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 16Thoracic 6Lymphoid 6Genitourinary 6Gastrointestinal 6Tumor-Agnostic 2Sarcoma 2Gynecologic 2Endocrine 2Dermatologic 2Breast 2Plasma cell 1Other solid neoplasm 1Head & Neck 1

Conditions

Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
antineoplaston AS 2-1 × Gynecologic × Clear all
NCT00003532 2017-12-12

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

Burzynski Research Institute

Phase 2 Terminated
7 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00003525 2017-09-29

Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva

Burzynski Research Institute

Phase 2 Terminated
8 enrolled
Gynecologic

Uterine Cervical Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡